Effects of V4c-ICL Implantation on Myopic Patients’ Vision-Related Daily Activities

Liu, Taixiang; Linghu, Shaorong; Pan, Le; Shi, Rong

doi:10.1155/2016/5717932

Cited by 16 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of patients (95.65%) with BCVA improved in a row or more. The safety index at 6 m and 24 m post operation were consistent with a previous study [14] . No significant change was found in the eye axial length .…”

Section: Resultssupporting

confidence: 91%

See 1 more Smart Citation

Long Term Assessment of the Quality of Visual-related Daily Activities after ICL (V4C) Implantation for Myopia and Myopic Astigmatism

Linghu

Liu²,

Liao

et al. 2018

Preprint

Self Cite

View full text Add to dashboard Cite

Background: The purpose of the study was to evaluate long-term quality of visual related daily activities after Central Hole Collamer Lens implantation to treat myopia and myopic astigmatism. Methods: This retrospective study included 46 eyes (23 patients) receiving an ICL-V4c implantation. The follow up time was at least 24 m. Uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), refraction, eye axis, intraocular pressure, endothelial cell density (ECD), vault, and the patients’ satisfaction related to vision related daily activities were recorded at 6 m and 24 m. Results: The mean spherical equivalents were -0.14 ± 0.21 D and -0.12 ± 0.33 D at 6 m and 24 m after surgery, respectively. UCVA of all eyes were equal to or better than preoperative BCVA. The BCVA at 6 m and 24 m after implantation were -0.03 ± 0.08 LogMAR, and −0.03 ± 0.11 LogMAR, respectively, which was statistically better (P = 0.031) than that of pre-operation value of 0.07 ± 0.12 LogMAR. There was no significant differences (P > 0.05) between the pre operation and post operation ECD.At 24 m post operation, 10% of the patients complained of difficulty driving at night, but most of patient had satisfactory or very satisfactory vision-related daily activity scores. Some patients, 13%, were worried about the long-term safety and efficacy of the V4c-ICL implantation. Conclusions: Patients were very satisfied with their vision related daily activities after V4c-ICL implantation. With time, some patients worried about the permanent safety and efficacy.

show abstract

Section: Resultssupporting

confidence: 91%

“…Evaluation of visual quality after ICL implantation was the focus of many studies [14,15,20]. Objective parameters such as contrast sensitivity and high-order aberration after V4c-ICL implantation were measured [21,22].…”

Section: Resultsmentioning

confidence: 99%

Long Term Assessment of the Quality of Visual-related Daily Activities after ICL (V4C) Implantation for Myopia and Myopic Astigmatism

Linghu

Liu²,

Liao

et al. 2018

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“… 10 2016 32 5 years 0.5 Liu et al . 11 2016 82 3 months 4.8 Kamiya et al . 12 2017 351 1 year 0.1 Goukon et al .…”

Section: Discussionmentioning

confidence: 99%

Posterior Chamber Phakic Intraocular Lens Implantation in Eyes with an Anterior Chamber Depth of Less Than 3 mm: A Multicenter Study

Kamiya

Shimizu

Igarashi

et al. 2018

Sci Rep

View full text Add to dashboard Cite

This study was aimed to assess the clinical outcomes of Visian ICL (hole ICL; STAAR Surgical, Inc.) implantation for the correction of myopic refractive errors in eyes having an anterior chamber depth (ACD) below the current manufacturer’s recommendation (<3.0 mm). We comprised 365 eyes of 201 consecutive patients (mean age ± standard deviation, 35.7 ± 7.5 years) with spherical equivalents of −8.66 ± 3.54 D. We evaluated the safety, efficacy, predictability, stability, intraocular pressure (IOP), endothelial cell density (ECD), and complications. The safety and efficacy indices were 1.12 ± 0.22 and 0.98 ± 0.22. At 1 year, 90% and 98% of eyes were within ± 0.5 and 1.0 D of the attempted correction, respectively. Changes in the manifest refraction from 1 week to 1 year postoperatively were −0.08 ± 0.34 D. The mean ECD loss was 0.2 ± 8.7%. No eyes showed a significant ECD loss (≥30%). We found no significant correlation between the ACD and the change in ECD (Pearson correlation coefficient r = −0.048, p = 0.360). No significant IOP rise or vision-threatening complication occurred at any time. These findings indicate that the surgical indication of ICL implantation should be reconsidered in terms of ACD.

show abstract

“…Liu et al offered confirmation in their retrospective study utilizing a different validated questionnaire,42 noting that “during the early postoperative follow-up period, halos occurred in 23 patients (54.8%). With time, halos gradually disappeared at 3 months after operation without any treatments.”43…”

Section: Introductionmentioning

confidence: 99%

The Implantable Collamer Lens with a central port: review of the literature

Packer¹

2018

OPTH

145

110

View full text Add to dashboard Cite

The purpose of this review is to summarize preclinical and clinical data from publications appearing in the peer-reviewed scientific literature relevant to the safety and effectiveness of the EVO Implantable Collamer Lens (ICL) posterior chamber phakic refractive lens with a central port (V4c Visian ICL with KS Aquaport, STAAR Surgical, Inc.). A literature search was conducted using PubMed.gov to identify all articles relating to the EVO ICL. Articles were examined for their relevance, and the references cited in each article were also searched for additional relevant publications. On the basis of a total of 67 preclinical studies and clinical reports, including effectiveness data on 1,905 eyes with average weighted follow-up of 12.5 months and safety data on 4,196 eyes with weighted average follow up of 14.0 months, the EVO ICL is safe and effective for the correction of a broad range of refractive errors. High levels of postoperative uncorrected visual acuity, refractive predictability, and stability demonstrate the effectiveness of the EVO ICL. Safety data suggest reduced rates of anterior subcapsular cataract and pupillary block compared with earlier models. Improved safety and proven effectiveness make EVO an attractive option for surgeons and patients.

show abstract

Effects of V4c-ICL Implantation on Myopic Patients’ Vision-Related Daily Activities

Cited by 16 publications

References 14 publications

Long Term Assessment of the Quality of Visual-related Daily Activities after ICL (V4C) Implantation for Myopia and Myopic Astigmatism

Long Term Assessment of the Quality of Visual-related Daily Activities after ICL (V4C) Implantation for Myopia and Myopic Astigmatism

Posterior Chamber Phakic Intraocular Lens Implantation in Eyes with an Anterior Chamber Depth of Less Than 3 mm: A Multicenter Study

The Implantable Collamer Lens with a central port: review of the literature

Contact Info

Product

Resources

About